Merck & Company, Inc. (MRK)
Latest news, insights and market data
Market Data
AI Insights
Merck faces competitive pressure as Summit Therapeutics claims its cancer drug ivonescimab is outperforming Keytruda in lung cancer treatment. This could challenge Merck's market position and profitability, especially as Keytruda's patent expiration approaches in 2028. Investors should keep an eye on how this rivalry develops.
Latest News
| Title | Published |
|---|---|
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know | about 9 hours ago |
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close. | about 9 hours ago |
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense | about 11 hours ago |
Which dow jones stocks are moving on Friday? Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session. | about 12 hours ago |
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill? Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill? | about 14 hours ago |
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill? Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare... | about 14 hours ago |
Was JNJ Stock Rally Actually Its Own? Was JNJ Stock Rally Actually Its Own? | about 14 hours ago |
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Which dow jones stocks are moving on Friday?
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...
Was JNJ Stock Rally Actually Its Own?
Was JNJ Stock Rally Actually Its Own?